# Symptom-driven Maintenance and Reliever Treatment to Prevent Exacerbations in COPD

> **NCT02477397** · PHASE3 · UNKNOWN · sponsor: **University Medical Center Groningen** · enrollment: 201 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** Spiromax Budesonide/formoterol
- **DRUG:** Diskus Fluticasone/salmeterol

## Key facts

- **NCT ID:** NCT02477397
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-05-01
- **Primary completion:** 2019-06-15
- **Final completion:** 2019-12-15
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2019-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02477397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02477397, "Symptom-driven Maintenance and Reliever Treatment to Prevent Exacerbations in COPD". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02477397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*